Literature DB >> 17947665

Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells.

Simona Ronchetti1, Giuseppe Nocentini, Rodolfo Bianchini, L Tibor Krausz, Graziella Migliorati, Carlo Riccardi.   

Abstract

CD28 is well characterized as a costimulatory molecule in T cell activation. Recent evidences indicate that TNFR superfamily members, including glucocorticoid-induced TNFR-related protein (GITR), act as costimulatory molecules. In this study, the relationship between GITR and CD28 has been investigated in murine CD8(+) T cells. When suboptimal doses of anti-CD3 Ab were used, the absence of GITR lowered CD28-induced activation in these cells whereas the lack of CD28 did not affect the response of CD8(+) T cells to GITR costimulus. In fact, costimulation of CD28 in anti-CD3-activated GITR(-/-) CD8(+) T cells resulted in an impaired increase of proliferation, impaired protection from apoptosis, and an impaired rise of activation molecules such as IL-2R, IL-2, and IFN-gamma. Most notably, CD28-costimulated GITR(-/-) CD8(+) T cells revealed lower NF-kappaB activation. As a consequence, up-regulation of Bcl-x(L), one of the major target proteins of CD28-dependent NF-kappaB activation, was defective in costimulated GITR(-/-) CD8(+) T cells. What contributed to the response to CD28 ligation in CD8(+) T cells was the early up-regulation of GITR ligand on the same cells, the effect of which was blocked by the addition of a recombinant GITR-Fc protein. Our results indicate that GITR influences CD8(+) T cell response to CD28 costimulation, lowering the threshold of CD8(+) T cell activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947665     DOI: 10.4049/jimmunol.179.9.5916

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice.

Authors:  M Galuppo; G Nocentini; E Mazzon; S Ronchetti; E Esposito; L Riccardi; P Sportoletti; R Di Paola; S Bruscoli; C Riccardi; S Cuzzocrea
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells.

Authors:  Ann J McPherson; Laura M Snell; Tak W Mak; Tania H Watts
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

Review 3.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

4.  Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Authors:  Chad Tang; James W Welsh; Patricia de Groot; Erminia Massarelli; Joe Y Chang; Kenneth R Hess; Sreyashi Basu; Michael A Curran; Maria E Cabanillas; Vivek Subbiah; Siqing Fu; Apostolia M Tsimberidou; Daniel Karp; Daniel R Gomez; Adi Diab; Ritsuko Komaki; John V Heymach; Padmanee Sharma; Aung Naing; David S Hong
Journal:  Clin Cancer Res       Date:  2016-09-20       Impact factor: 12.531

Review 5.  Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies.

Authors:  Xue Han; Matthew D Vesely
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-20       Impact factor: 6.813

Review 6.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

7.  Loss of T regulatory cell suppression following signaling through glucocorticoid-induced tumor necrosis receptor (GITR) is dependent on c-Jun N-terminal kinase activation.

Authors:  Anthony Joetham; Hiroshi Ohnishi; Masakazu Okamoto; Katsuyuki Takeda; Michaela Schedel; Joanne Domenico; Azzeddine Dakhama; Erwin W Gelfand
Journal:  J Biol Chem       Date:  2012-03-29       Impact factor: 5.157

8.  Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours.

Authors:  Jinhua Piao; Yosuke Kamimura; Hideyuki Iwai; Yujia Cao; Keisuke Kikuchi; Masaaki Hashiguchi; Taro Masunaga; Hongsi Jiang; Kouichi Tamura; Shimon Sakaguchi; Miyuki Azuma
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

Review 9.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

10.  Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target.

Authors:  Sylvaine You; Lynn Poulton; Steve Cobbold; Chih-Pin Liu; Michael Rosenzweig; Douglas Ringler; Wen-Hui Lee; Berta Segovia; Jean-François Bach; Herman Waldmann; Lucienne Chatenoud
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.